SPOREs
Breast
Projects
Combination therapy for HER2-positive breast cancer
Aim 1: Evaluate biomarkers of sensitivity and resistance to HER2-directed therapy.
Aim 2: Evaluate combinations of trastuzumab and signaling inhibitors.
Aim 3: Conduct unbiased screens for targets whose inhibition sensitizes to HER2-directed treatments.
Key Personnel:
Thomas M. Roberts, PhD – DFCI
Eric P. Winer, MD – DFCI
Matthew L. Freedman, MD – DFCI
Randy King, MD, PhD – HMS
Jean Zhao, PhD – DFCI
Zoltan Szallasi, MD – CHB
Gerburg M. Wulf, MD – BIDMC
Ian E. Krop, MD, PhD – DFCI
Recent Publications:
Zhao, J.J., Cheng, H. Jia,SD, Wang, L., Gjoerup, OV., Mikiami, A. and Roberts, T.M. (2006) The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 103(44):16296-16300.
Zhao, J.J. and Roberts, T.M. (2006) PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target. Sci. STKE 2006, 365: pe52.
Gjoerup OJ, Wu J, Chandler-Militello D, William GL, Zhao JJ, Jat PS and Roberts TM. A surveillance mechanism linking Bub1 loss to p53 activation. Proc Natl Acad Sci U S A, 2007; 104: 8334-8339.
Utermark T, Roberts TM and Zhao JJ. The requirement for the p110α isoform of PI3K in Polyoma middle T antigen mediated transformation. J. Virology, 2007; 81(13):7069-707.
Boehm JS, Zhao JJ*, Yao J, Kim SY, Dunn IF, Sjostrom AK, Garraway LA, Weremowicz, S, Stewart, CJ, Mulvey LA, Hill DE, Vidal M, Grenier J, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K and Hahn W. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell, 2007; 129:1065-1079. * Co-first and Co-corresponding author.
Jia S, Liu Z, Zhang S, Liu P, Lee S, Zhang J, Lee S, Zhang J, Signoretti S, Loda M, and Roberts TM, and Zhao JJ. Essential roles for the p110beta isoform of PI3K in cell growth, metabolism and tumorignensis. Nature, 2008, in press. Submitted to PMC, NIHMSID 56189.
